Core Viewpoint - The company Jinshi Yiyao (300434.SZ) is a leading brand owner of cold medicine products in China, specifically known for "Kuaike" and "Xiaokuaike" [1] Product Portfolio - The company has developed a product cluster focused on adult and pediatric cough relief over more than 20 years of brand accumulation [1] - Key products include: - "Kuaike" compound paracetamol and amantadine capsules for alleviating symptoms of common colds and influenza, also used for prevention and treatment of influenza [1] - "Xiaokuaike" pediatric paracetamol and chlorpheniramine granules for relieving symptoms of common colds and influenza in children [1] - "Kuaike Qing" oseltamivir phosphate capsules for treating and preventing type A and B influenza in adults and children aged 1 year and older [1] - Additional products include: - Yumeijia Mamin syrup, Pudilan anti-inflammatory tablets, antiviral oral liquid, compound honeysuckle granules, cold-clearing granules, ibuprofen granules, and various cough relief granules [1]

Core Viewpoint - The company Jinshi Yiyao (300434.SZ) is a leading brand owner of cold medicine products in China, specifically known for "Kuaike" and "Xiaokuaike" [1] Product Portfolio - The company has developed a product cluster focused on adult and pediatric cough relief over more than 20 years of brand accumulation [1] - Key products include: - "Kuaike" compound paracetamol and amantadine capsules for alleviating symptoms of common colds and influenza, also used for prevention and treatment of influenza [1] - "Xiaokuaike" pediatric paracetamol and chlorpheniramine granules for relieving symptoms of common colds and influenza in children [1] - "Kuaike Qing" oseltamivir phosphate capsules for treating and preventing type A and B influenza in adults and children aged one year and older [1] - Additional products include: - Yumeijia Mamin syrup, Pudilan anti-inflammatory tablets, antiviral oral liquid, compound honeysuckle granules, cold-clearing heat granules, ibuprofen granules, and various cough relief granules [1] - The product range meets diverse consumer needs for prevention, alleviation, and treatment of colds [1]

Group 1: Company Strategy and Development - The company adheres to a dual strategy of independent and collaborative research and development, enhancing its long-term development through strategic investments and internal resource integration [1] - The company aims to become a trusted and preferred provider of professional healthcare products, focusing on a unified operational system across R&D, marketing, and production [2] - The company plans to implement a four-pronged growth model encompassing OTC, prescription drugs, traditional Chinese medicine, and health products to support high-quality development [2] Group 2: Marketing and Sales Achievements - The company has established a comprehensive marketing system, covering over 3,000 chain pharmacies and approximately 240,000 cooperative chain stores, reaching over 90% of cities and 70% of districts nationwide [2] - The company’s online channel strategy includes partnerships with e-commerce platforms to enhance product accessibility and consumer engagement [2] Group 3: Financial Performance - In 2024, the pharmaceutical segment generated revenue of 915 million yuan, accounting for 82.96% of total revenue, with the "Kuaike" series contributing 612 million yuan, representing 55.49% of total revenue [3] - The company’s cold and flu medications account for approximately 56% of total revenue [4] Group 4: Product Development and Market Position - The "Kuaike" cold medicine has ranked first in the annual comprehensive statistics of non-prescription drugs in China for three consecutive years from 2021 to 2023 [3] - The company has successfully launched the "Kuaike Qing" oseltamivir capsules and has received re-listing permits for other products [1] Group 5: Future Plans and Challenges - The company is actively preparing for the flu season by optimizing production capacity and ensuring smooth supply channels [5] - The company is exploring opportunities in traditional Chinese medicine, developing high-quality products to enhance market share in this sector [5]